Journal: Signal Transduction and Targeted Therapy

Article Title: Glycolytic heterogeneity drives metabolic-targeted therapy in pancreatic ductal adenocarcinoma

doi: 10.1038/s41392-025-02546-8

Figure Lengend Snippet: Glycolytic Profiling and LDHA Inhibition Reveal Differential Sensitivity Across PDAC Cell Lines. a Heatmap of glycolytic signature expression, reported as normalized transcript per million (nTPM) across five PDAC cell lines from Human Protein Atlas. b Western blot analysis of LDHA expression in PL45, SW1990, PANC-1, MIAPaCa-2, and HPAF-II cells. c Glycolytic activity in PL45, SW1990, PANC-1, MIAPaCa-2, and HPAF-II cells after LDHA-i treatment, measured as extracellular acidification rate (ECAR). Each dot represents a biological replicate ( n = 6 per group). Data are represented as mean ± SD. Statistical analysis performed with a paired t -test. d Viability assay in MIAPaCa-2 (green), PANC-1 (blue), PL45 (purple), HPAF-II (red), and HPDE6c7 (brown) cells upon LDHA-i treatment at 24 and 48 h. Boxplots display IC50 values for each time point across cell lines, with statistical significance assessed by paired t -test ( n = 2 per group). On the right, GR50 and GRmax values represent drug potency and efficacy, respectively

Article Snippet: The PL45 (CRL-2558), SW1990 (CRL-2172), PANC-1 (CRL-1469), HPAF-II (CRL-1997), and MIAPaCa-2 (CRL-1420) cell lines were purchased from ATCC.

Techniques: Inhibition, Expressing, Western Blot, Activity Assay, Viability Assay

Journal: Signal Transduction and Targeted Therapy

Article Title: Glycolytic heterogeneity drives metabolic-targeted therapy in pancreatic ductal adenocarcinoma

doi: 10.1038/s41392-025-02546-8

Figure Lengend Snippet: Metabolomic, Proteomic, and Transcriptomic Profiling Uncovers the Impact of LDHA Inhibition in PDAC. a Amount of lactate in MIAPaCa-2 and PL45 cells at the basal level (gray) and after LDHA inhibition (blue). Each dot represents a biological replicate ( n = 6 per group). Data are shown as normalized intensity and are represented as mean ± SD. Statistical significance was calculated with a paired t -test. b Pathway enrichment analysis performed on metabolomics data in MIAPaCa-2 cells at basal level and after LDHA inhibition. The x -axis indicates pathway impact based on metabolite expression. The y -axis indicates p value transformed as −Log 10 . c Significant results from enrichment analysis performed on proteomics data in MIAPaCa-2 cells after LDHA inhibition. The x -axis indicates the normalized enrichment score. The label shows p value transformed as −Log 10 . d Enrichment plots for glycolysis and hypoxia in MIAPaCa-2 cells treated with LDHA-i. Normalized enrichment score and p value are reported in the figure. e Hallmarks significantly upregulated in PDAC patient samples exhibiting High glycolytic profile compared to those with Low glycolytic profile (left). Hallmarks significantly downregulated in MIAPaCa-2 cells following treatment with LDHA-i (right). The y -axis indicates the normalized enrichment score

Article Snippet: The PL45 (CRL-2558), SW1990 (CRL-2172), PANC-1 (CRL-1469), HPAF-II (CRL-1997), and MIAPaCa-2 (CRL-1420) cell lines were purchased from ATCC.

Techniques: Metabolomic, Inhibition, Expressing, Transformation Assay

Journal: Signal Transduction and Targeted Therapy

Article Title: Glycolytic heterogeneity drives metabolic-targeted therapy in pancreatic ductal adenocarcinoma

doi: 10.1038/s41392-025-02546-8

Figure Lengend Snippet: Integrative multiomics analysis correlates molecular signatures in PDAC. a Clustered image map of variables selected by multiblock partial least squares discriminant analysis (PLS-DA) based on omics datasets. Samples are displayed as rows, and selected features in columns. Histograms represent significant functional analysis results for proteins (light green), pathway analysis for metabolites (red), and enrichment analysis for lipids (purple). Statistical significance is expressed as −Log 10 transformed p values. b Circos plot from multiblock PLS-DA performed on proteomic (green), metabolomic (red), and lipidomic (purple) data in MIAPaCa-2 cells treated with LDHA-i. The plot shows correlations between 0.7 and −0.7 across proteins, metabolites, and lipids, represented on the side quadrants. The internal connecting lines show positive (light brown) and negative (black) correlations. c Network plot of correlated features derived by multiblock PLS-DA. Each node represents a variable, color-coded by type. The color of the edges indicates positive (light brown) or negative (black) correlations greater than ±0.7 between variables of different types

Article Snippet: The PL45 (CRL-2558), SW1990 (CRL-2172), PANC-1 (CRL-1469), HPAF-II (CRL-1997), and MIAPaCa-2 (CRL-1420) cell lines were purchased from ATCC.

Techniques: Functional Assay, Transformation Assay, Metabolomic, Derivative Assay

Journal: Discover Oncology

Article Title: Integrative immunogenomic profiling identifies CALU as a brown adipocyte–linked modulator of progression and treatment response in pancreatic cancer

doi: 10.1007/s12672-025-04309-x

Figure Lengend Snippet: Expression of CALU in Pancreatic Cancer Cell Lines. A mRNA Expression of CALU in 48 Pancreatic Cancer Cell Lines. B RT-PCR analysis was performed to validate CALU mRNA expression levels in the normal pancreatic cell line MIA PaCa-2 and pancreatic cancer cell lines AsPC-1, HPDE6-C7, and SW1990

Article Snippet: The human pancreatic cancer cell lines HPDE6-C7, SW1990, and AsPC-1, along with the human normal pancreatic cell line MIA PaCa-2, were obtained from ATCC.

Techniques: Expressing, Reverse Transcription Polymerase Chain Reaction